Lessons from the GHOST-EU registry.

Bifurcations are increasingly being treated with bioresorbable vascular scaffolds (BVS) and accounted for about 25% of patients treated in the large multicentre GHOST-EU registry. This registry, along with bench testing, has provided a glimpse of the techniques and limitations of treating bifurcations with BVS. The provisional strategy remains the default approach to bifurcation treatment with BVS. If correctly performed, SB dilatation, T-kissing inflation, crossover to side branch stenting and elective double stenting are feasible without causing scaffold disruption. Theoretically, when the scaffolds are resorbed, the normal bifurcation anatomy, flow and vascular function will be restored, while jailed SBs will be liberated. However, data from the GHOST-EU registry are awaited to confirm the long-term safety and efficacy of BVS in coronary bifurcations.

[1]  C. Hamm,et al.  A true bifurcational stenosis treated with a bioresorbable vascular scaffold and a drug‐eluting metallic stent: Degradable meets durable , 2015, Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions.

[2]  S. Achenbach,et al.  Contemporary practice and technical aspects in coronary intervention with bioresorbable scaffolds: a European perspective. , 2015, EuroIntervention : journal of EuroPCR in collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology.

[3]  Antonio Colombo,et al.  Percutaneous coronary intervention with everolimus-eluting bioresorbable vascular scaffolds in routine clinical practice: early and midterm outcomes from the European multicentre GHOST-EU registry. , 2015, EuroIntervention : journal of EuroPCR in collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology.

[4]  J. Ormiston,et al.  Absorb everolimus-eluting bioresorbable scaffolds in coronary bifurcations: a bench study of deployment, side branch dilatation and post-dilatation strategies. , 2015, EuroIntervention : journal of EuroPCR in collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology.

[5]  A. Colombo,et al.  The absorb bioresorbable vascular scaffold in coronary bifurcations: insights from bench testing. , 2014, JACC. Cardiovascular interventions.

[6]  A. Colombo,et al.  Optical coherence tomography of a bifurcation lesion treated with bioresorbable vascular scaffolds with the "mini-crush" technique. , 2013, JACC. Cardiovascular interventions.

[7]  P. Serruys,et al.  Five-year clinical and functional multislice computed tomography angiographic results after coronary implantation of the fully resorbable polymeric everolimus-eluting scaffold in patients with de novo coronary artery disease: the ABSORB cohort A trial. , 2013, JACC. Cardiovascular interventions.

[8]  A. Colombo,et al.  Which patients could benefit the most from bioresorbable vascular scaffold implant: from clinical trials to clinical practice. , 2013, Minerva cardioangiologica.

[9]  Thierry Lefèvre,et al.  Provisional side branch stenting for the treatment of bifurcation lesions. , 2010, EuroIntervention : journal of EuroPCR in collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology.

[10]  I. Moussa,et al.  When are two stents needed? Which technique is the best? How to perform? , 2010, EuroIntervention : journal of EuroPCR in collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology.

[11]  Antonio Colombo,et al.  Bifurcation disease: what do we know, what should we do? , 2008, JACC. Cardiovascular interventions.